We are live on ! Find out more
ZNTL icon

Zentalis Pharmaceuticals
ZNTL

120 hedge funds and large institutions have $1.27B invested in Zentalis Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 48 increasing their positions, 35 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

37% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 35

0.99% less ownership

Funds ownership: 104.19% → 103.2% (-0.99%)

5% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 22

2% less funds holding

Funds holding: 122 → 120 (-2)

21% less capital invested

Capital invested by funds: $1.61B → $1.27B (-$345M)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

Holders
120
Holders Change
-2
Holders Change %
-1.64%
% of All Funds
2.07%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
21
Increased
48
Reduced
35
Closed
22
Calls
$3.79M
Puts
–
Net Calls
+$3.79M
Net Calls Change
+$2.27M

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$47.5M
2
EAM
Eventide Asset Management
Massachusetts
+$23.4M
3
APM
Avidity Partners Management
Texas
+$17.4M
4
SI
Sofinnova Investments
California
+$6.97M
5
IHAM
Integral Health Asset Management
New York
+$5.74M

Top Sellers

Rank Fund Capital Flow
1
Viking Global Investors
Viking Global Investors
Connecticut
-$56.9M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$56.9M
3
PCH
Polar Capital Holdings
United Kingdom
-$15.7M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$10.6M
5
Fiera Capital (Canada)
Fiera Capital (Canada)
Quebec, Canada
-$10.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
KCM
26
Kennedy Capital Management
Missouri
$5.26M +$3.32M +121,408 +100%
Norges Bank
27
Norges Bank
Norway
$5.02M -$2.74M -100,056 -30%
Axa
28
Axa
France
$4.96M +$26.9K +985 +0.4%
UBS AM
29
UBS AM
Illinois
$4.89M +$2.23M +81,401 +56%
Voloridge Investment Management
30
Voloridge Investment Management
Florida
$4.54M -$1.92M -70,076 -25%
Ameriprise
31
Ameriprise
Minnesota
$3.99M +$298K +10,905 +6%
Rafferty Asset Management
32
Rafferty Asset Management
New York
$3.98M +$1.6M +58,538 +47%
AAA
33
Affinity Asset Advisors
New York
$3.68M +$2.73M +100,000 +143%
Citigroup
34
Citigroup
New York
$3.66M +$1.04M +37,965 +29%
NIP
35
Nicholas Investment Partners
California
$3.44M +$4.34M +158,704 New
ECM
36
ExodusPoint Capital Management
New York
$3.42M +$4.32M +157,969 New
Bank of New York Mellon
37
Bank of New York Mellon
New York
$3.31M +$942K +34,429 +29%
Ensign Peak Advisors
38
Ensign Peak Advisors
Utah
$3.29M +$1.87M +68,327 +82%
CS
39
Candriam SCA
Luxembourg
$2.77M – – –
N
40
Nuveen
North Carolina
$2.68M +$307K +11,239 +10%
Bank of America
41
Bank of America
North Carolina
$2.65M -$5.12M -187,332 -61%
Barclays
42
Barclays
United Kingdom
$2.53M +$3.09M +113,153 +3,285%
Swiss National Bank
43
Swiss National Bank
Switzerland
$2.34M – – –
Millennium Management
44
Millennium Management
New York
$2.18M +$2.75M +100,672 New
Morgan Stanley
45
Morgan Stanley
New York
$2.11M -$6.79M -248,345 -72%
Walleye Capital
46
Walleye Capital
New York
$1.85M +$2.34M +85,529 New
TD Asset Management
47
TD Asset Management
Ontario, Canada
$1.78M +$2.73K +100 +0.1%
Russell Investments Group
48
Russell Investments Group
United Kingdom
$1.73M +$54.1K +1,978 +3%
BNP Paribas Financial Markets
49
BNP Paribas Financial Markets
France
$1.66M +$2.09M +76,564 New
Susquehanna International Group
50
Susquehanna International Group
Pennsylvania
$1.63M +$1.81M +66,153 +746%
1
2
3 4 5

ZNTL Hedge Fund Activity: Q3 2022 in Review

120 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q3 2022, worth a combined $1.27B — down 21% from $1.61B a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of ZNTL and 21 opened new positions — a net loss of 1 holder — while 35 trimmed existing stakes and 48 added.

The largest buyer was Wellington Management Group, adding an estimated $47.5M. The largest seller was Viking Global Investors, exiting entirely with an estimated $56.9M sold.

  • 120 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q3 2022, down from 122 in Q2 2022.
  • Funds reported $1.27B of Zentalis Pharmaceuticals stock for Q3 2022, down 21% quarter-over-quarter.
  • 21 funds opened new Zentalis Pharmaceuticals positions in Q3 2022 and 22 closed out, a net change of -1 holder.
  • The largest Zentalis Pharmaceuticals buyer in Q3 2022 was Wellington Management Group, an estimated $47.5M added.
  • The largest Zentalis Pharmaceuticals seller in Q3 2022 was Viking Global Investors, an estimated $56.9M sold.

Based on aggregated 13F filings for Q3 2022.